Develops drugs for chronic hepatitis B infection.
Jun 2026Revenue $182M/yrExpenses $32.7M/yr
Reached break-even Jan 2026
Figures by year
When did Arbutus Biopharma become profitable?
Its revenue passed its expenses in Jan 2026. In the 12 months to Jun 2026, revenue was $182M and expenses $32.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $14.1M | $52.2M | −$38.2M |
| Dec 2024 | $6.17M | $82.5M | −$76.3M |
| Dec 2023 | $18.1M | $96.2M | −$78.1M |
| Dec 2022 | $39.0M | $104M | −$65.5M |
| Dec 2021 | $11.0M | $84.5M | −$73.5M |
| Dec 2020 | $6.91M | $64.7M | −$57.8M |
| Dec 2019 | $6.01M | $150M | −$144M |
| Dec 2018 | $5.95M | $95.7M | −$89.8M |
| Dec 2017 | $10.7M | $122M | −$111M |
| Dec 2016 | $1.49M | $493M | −$492M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.